Compare 8x8 Inc (EGHT) vs Pfizer Inc (PFE) Price & Performance

EGHT trades at $1.995, down 10.94% in the past 24 hours, with a bullish technical signal from moving averages but neutral oscillators. The company reported record service revenue in Q1 2027, beating earnings estimates for the fourth consecutive quarter. Recent news highlights AI expansion and a new partner program aimed at customer growth.

The outlook is mixed: strong revenue growth and AI adoption offer upside, but high P/E of 71.33 and negative net income in 2025 pose risks. Analyst consensus is a buy with a $3.13 target, though debt levels and profitability challenges require monitoring for sustained investor confidence.

Pfizer (PFE) trades at $27.05, up 1.16% with a bullish technical signal and consistent earnings beats in recent quarters. Revenue remains stable around $62-63 billion, though net income is projected to decline in 2026. The stock shows strong profitability margins and a solid balance sheet, but faces headwinds from patent expirations and competitive pressures.

The outlook is mixed: valuation multiples appear reasonable, and analyst consensus leans hold with a $27.86 target. Key risks include execution on pipeline catalysts and margin compression. Upside depends on successful drug launches and cost management amid a challenging revenue environment.